Enovis Co. (NYSE:ENOV) Short Interest Update

Enovis Co. (NYSE:ENOV) was the target of a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 4,450,000 shares, an increase of 6.7% from the December 15th total of 4,170,000 shares. Based on an average daily trading volume, of 669,300 shares, the days-to-cover ratio is currently 6.6 days. Approximately 8.1% of the shares of the stock are short sold.

Analyst Ratings Changes

Several equities analysts have recently weighed in on ENOV shares. Needham & Company LLC restated a “buy” rating and set a $65.00 price objective on shares of Enovis in a research report on Thursday, November 7th. Evercore ISI reduced their target price on shares of Enovis from $62.00 to $58.00 and set an “outperform” rating for the company in a report on Tuesday, October 1st. Finally, JMP Securities assumed coverage on Enovis in a report on Thursday, October 3rd. They issued an “outperform” rating and a $62.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Enovis has a consensus rating of “Moderate Buy” and an average target price of $67.00.

Institutional Investors Weigh In On Enovis

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ENOV. UMB Bank n.a. raised its stake in shares of Enovis by 128.2% during the 4th quarter. UMB Bank n.a. now owns 778 shares of the company’s stock worth $34,000 after purchasing an additional 437 shares in the last quarter. Pinnacle Bancorp Inc. increased its holdings in Enovis by 54.5% in the fourth quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company’s stock worth $37,000 after buying an additional 300 shares during the last quarter. DekaBank Deutsche Girozentrale bought a new position in Enovis during the third quarter valued at approximately $55,000. Benjamin F. Edwards & Company Inc. lifted its stake in Enovis by 28.1% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,691 shares of the company’s stock valued at $76,000 after acquiring an additional 371 shares during the last quarter. Finally, FMR LLC grew its position in Enovis by 20.5% in the third quarter. FMR LLC now owns 2,840 shares of the company’s stock worth $122,000 after acquiring an additional 484 shares in the last quarter. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Enovis Trading Up 2.7 %

Enovis stock traded up $1.21 during midday trading on Friday, reaching $46.68. The stock had a trading volume of 541,602 shares, compared to its average volume of 559,026. The firm’s fifty day simple moving average is $45.85 and its two-hundred day simple moving average is $44.35. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12. Enovis has a twelve month low of $38.27 and a twelve month high of $65.03. The firm has a market cap of $2.61 billion, a price-to-earnings ratio of -21.32 and a beta of 1.94.

Enovis (NYSE:ENOV) last issued its earnings results on Wednesday, November 6th. The company reported $0.73 EPS for the quarter, topping the consensus estimate of $0.62 by $0.11. The business had revenue of $505.22 million during the quarter, compared to analysts’ expectations of $504.44 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. Enovis’s revenue was up 21.0% compared to the same quarter last year. During the same quarter last year, the firm posted $0.56 earnings per share. Equities analysts anticipate that Enovis will post 2.79 EPS for the current fiscal year.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.